Table 8. Virus neutralization titers for secondary DENV-2 infected serum samples from dengue fever patients.
| Serum # | Country of Origin | DPO1 | Virus | 90% FRμNT titer2 | Calculated 90% FRμNT Titer3 |
| 9 | Taiwan | 14 | DENV-1 | 6400 | 7378 |
| DENV-2 | 6400 | 11,174 | |||
| DENV-3 | 800 | 2376 | |||
| DENV-4 | 800 | 589 | |||
| JEV | <50 | 83 | |||
| 10 | Taiwan | 18 | DENV-1 | 25600 | 25,334 |
| DENV-2 | 6400 | 6743 | |||
| DENV-3 | 320 | 3024 | |||
| DENV-4 | 800 | 991 | |||
| JEV | 50 | 103 | |||
| 17 | Taiwan | 14 | DENV-1 | 6400 | 4179 |
| DENV-2 | 3200 | 2076 | |||
| DENV-3 | 3200 | 2898 | |||
| DENV-4 | 800 | 915 | |||
| JEV | <50 | 3 | |||
| 0169 | Puerto Rico | 6 | DENV-1 | 200 | 306 |
| DENV-2 | 3200 | 3821 | |||
| DENV-3 | 800 | 934 | |||
| DENV-4 | 200 | 167 | |||
| WNV | <50 | 59 | |||
| JEV | <50 | 17 | |||
| 9608 | Puerto Rico | 13 | DENV-1 | 50 | 79 |
| DENV-2 | 400 | 431 | |||
| DENV-3 | 100 | 95 | |||
| DENV-4 | 400 | 526 | |||
| WNV | <50 | 74 | |||
| JEV | <50 | 25 | |||
| 8867 | Puerto Rico | 7 | DENV-1 | 200 | 366 |
| DENV-2 | 3200 | 3177 | |||
| DENV-3 | 100 | 135 | |||
| DENV-4 | 800 | 1341 | |||
| WNV | 50 | 122 | |||
| JEV | <50 | 38 |
1
days post onset of symptoms.
2
Last positive titer in 90% Focus-reduction micro-neutralization (FRμNT) assay.
3
Calculated actual 90% neutralization titers based on a nonlinear regression of the FRμNT data using a variable slope sigmoidal dose-response model.